Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
2011 3
2012 8
2013 8
2014 12
2015 21
2016 30
2017 29
2018 23
2019 21
2020 36
2021 33
2022 38
2023 40
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

272 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.
Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, Odunsi K. Zsiros E, et al. Among authors: attwood km. JAMA Oncol. 2021 Jan 1;7(1):78-85. doi: 10.1001/jamaoncol.2020.5945. JAMA Oncol. 2021. PMID: 33211063 Free PMC article. Clinical Trial.
Lorazepam Stimulates IL6 Production and Is Associated with Poor Survival Outcomes in Pancreatic Cancer.
Cornwell AC, Tisdale AA, Venkat S, Maraszek KE, Alahmari AA, George A, Attwood K, George M, Rempinski D, Franco-Barraza J, Seshadri M, Parker MD, Cortes Gomez E, Fountzilas C, Cukierman E, Steele NG, Feigin ME. Cornwell AC, et al. Among authors: attwood k. Clin Cancer Res. 2023 Sep 15;29(18):3793-3812. doi: 10.1158/1078-0432.CCR-23-0547. Clin Cancer Res. 2023. PMID: 37587561 Free PMC article.
Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer.
Cannioto RA, Attwood KM, Davis EW, Mendicino LA, Hutson A, Zirpoli GR, Tang L, Nair NM, Barlow W, Hershman DL, Unger JM, Moore HCF, Isaacs C, Hobday TJ, Hortobagyi GN, Gralow JR, Albain KS, Budd GT, Ambrosone CB. Cannioto RA, et al. Among authors: attwood km. JAMA Netw Open. 2023 May 1;6(5):e2311673. doi: 10.1001/jamanetworkopen.2023.11673. JAMA Netw Open. 2023. PMID: 37140922 Free PMC article.
Predictive and Prognostic Implications of Circulating CX3CR1+ CD8+ T Cells in Non-Small Cell Lung Cancer Patients Treated with Chemo-Immunotherapy.
Abdelfatah E, Long MD, Kajihara R, Oba T, Yamauchi T, Chen H, Sarkar J, Attwood K, Matsuzaki J, Segal BH, Dy GK, Ito F. Abdelfatah E, et al. Among authors: attwood k. Cancer Res Commun. 2023 Mar 30;3(3):510-520. doi: 10.1158/2767-9764.CRC-22-0383. eCollection 2023 Mar. Cancer Res Commun. 2023. PMID: 37009132 Free PMC article.
Galectin-3 expression in donor T cells reduces GvHD severity and lethality after allogeneic hematopoietic cell transplantation.
Mohammadpour H, Tsuji T, MacDonald CR, Sarow JL, Rosenheck H, Daneshmandi S, Choi JE, Qiu J, Matsuzaki J, Witkiewicz AK, Attwood K, Blazar BR, Odunsi K, Repasky EA, McCarthy PL. Mohammadpour H, et al. Among authors: attwood k. Cell Rep. 2023 Mar 28;42(3):112250. doi: 10.1016/j.celrep.2023.112250. Epub 2023 Mar 15. Cell Rep. 2023. PMID: 36924493 Free PMC article.
Desmoglein compensation hypothesis fidelity assessment in Pemphigus.
Sielski L, Baker J, DePasquale MC, Attwood K, Seiffert-Sinha K, Sinha AA. Sielski L, et al. Among authors: attwood k. Front Immunol. 2022 Sep 23;13:969278. doi: 10.3389/fimmu.2022.969278. eCollection 2022. Front Immunol. 2022. PMID: 36211362 Free PMC article.
272 results